Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19) (DEFEAT-COVID study)
- Funded by LifeArc
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
LifeArcPrincipal Investigator
Unspecified Unspecified UnspecifiedResearch Location
United KingdomLead Research Institution
Ashford and St Peter's Hospitals NHS Foundation Trust, Guangdong Uni-Innovation Pharmaceuticals Co., Ltd.Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
A group of London hospital trusts in collaboration with researchers in China, and with funding from LifeArc, is set to commence clinical trial testing of leflunomide - a drug licensed to treat rheumatoid arthritis - in hospitalised COVID-19 patients. Leflunomide has previously been investigated in a small pilot study conducted in Wuhan, China. Patients with moderate or severe clinical symptoms of COVID-19 who were treated with leflunomide demonstrated favourable clinical outcomes with a shorter clinical recovery time compared to the placebo arm, and no side effects were observed. This LifeArc funded study now aims to explore these initial findings in a larger patient cohort.